Vaccines, Thursday 1 March 2018


Organiser's Welcome Remarks


Chair's Opening Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng

Venture capital funding for the biotech industry: A case study

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important priorities than to invest in early stage companies, the role of the VC becomes even more crucial and necessary for success. Investigate how VC helps biotech to take flight in the competitive generics and biosimilar-focused Asia market.
John Connolly

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
Panel discussion

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?

Speed Networking


Exhibition Visit & Networking Refreshments

Asia immunisation program


Chair's Opening Remarks

Tabassum Khan

Role of manufacturers in clearing vaccines misconception

  •     Investigating the origin of misconception regarding vaccination
  •     Existing educational and advertising efforts and future actions required to clear such misconception
  •     Religion vs science: Is there a violation in religion to get vaccinated?
  •     Updates on halal vaccines and plans forward
Ayan Dey

Building affordable and sustainable vaccines framework for neglected diseases in Asia

  •     Quick overview of International Vaccine Institute (IVI) and its achievement so far
  •     Building an effective tech transfer model for quality local accessibility 
  •     Updates on IVI latest projects and collaboration opportunities
Trần Hiển Nguyễn

Vaccination program in Vietnam and its health impact

  •     Sharing of current and upcoming vaccination program in Vietnam
  •     Measuring success of current initiatives and strategies to improve next step in nationwide vaccination
  •     Preparing for epidemic and infectious diseases: Key steps and considerations

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 1: Upcoming vaccines in Asia and how to prepare for it

Table 2: Sustainable vaccines strategies in global health, high-income and private sector

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: What can we learn fromCAR-T, PDL1, Cancer Vaccines successes, and what’s next in Asia?

Table 6: CRISPR & Precision medicine

Table 7: AI& Big data in drug discovery

Table 8: IoT and blockchain in clinical studies

Table 9: Pricing & Reimbursement strategies in Asia

Table 10: What can we do to reconcile our diversified pharma regulations in Asia?

Table 11: Bringing it together: Roles of Patient, Pharma, Hospital and Government in Drug Development


Exhibition Visit & Networking Lunch

Vaccines Manufacturing: Cost & Efficiency


Chair's Opening Remarks

Dr GS Reddy

Addressing the complexity in low cost, high volume vaccines manufacturing

    style="font-size: 10.0pt;">
  •     Exploring strategies to meet regulatory requirement in low cost, high volume quality manufacturing
  •     Cost vs innovation: How do we continuously innovate within the low profit margin business
  •     Case study and analysis
Do Tuan Dat

A case study of Vabiotech: Challenges in vaccine development and production in Vietnam

    style="font-size: 10.0pt;">
  •     Challenges in accessing to technology for better upstream and downstream process
  •     Strategies to help regulators keep up with new technology such as cell-based vaccines for approval
  •     Challenges in getting funding to manufacture vaccines in Vietnam

Effective vaccine tech transfer (TT) for sustainable, quality local accessibility

  • Ensuring equity between partners and equitable TT meets both parties’ expectations
  • Freedom to operate once the recipient receive the TT to ensure production sustainability
  • Building regulatory capacity for quality monitoring and approval

Exhibition Visit & Networking Refreshments

Asia Vaccine Innovation

Paul Howley

Overcoming the complexities of conjugate vaccine production

  •     Exploring existing challenges in managing the complexities in conjugate vaccine production 
  •     Discovering alternative expression systems for vaccine cultivation
  •     Case study: Using in-vivo recombinant technology to produce conjugate vaccines

Next generation universal vaccines

  •     Discovering novel antigens using reverse vaccinology
  •     Too good to be true? What are the drawbacks and limitations?
  •     A universal influenza vaccine: What have we learnt so far?

Upscaling thermostable vaccines: Where are we now?

Thermostable vaccines are an alternative solution to overcome vaccine distribution limitations in developing countries. What’s the update on progress after several years of R&D and discussion? What needs to be done to successful upscale thermostable vaccines for more efficient vaccination effort in developing regions? Case studies will also be discussed during this presentation.

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 07/Dec/17 03:05

Vaccines, Friday 2 March 2018


Organiser's Welcome Remarks


Chair's Opening Remarks

Disruption & Digitalisation


Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.

CAR-T therapy, the next miracle drug in the making

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. However, the rapid advances still stir fears about the safety of the drug after failed cases and deaths on some pharma sponsored trials. With more companies putting their CAR-T pipeline to test in the market, how can regulators ensure patient safety? And from a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Even if it becomes fully approved for commercial deployment, what needs to be done to help patients afford the sky high cost of immunotherapy?
Ivor Lim

Working with increasingly informed and empowered patients in the digital ageEducated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.

Exhibition Visit & Networking Refreshments

Delivery Platforms


Chair's Opening Remarks

Tim Collard

Low cost, flexible universal adjuvant & delivery system to orally deliver PGT and third party inactivated vaccines for infectious diseases

  •     Traditional vs new generation vaccines to protect against infectious diseases
  •     Building effective vaccines against genetic shifts and the appearance of mutated strains
  •     Moving beyond animal vaccines: How PGT platforms are being developed for human usage
Levent Liu

A novel platform technology for vaccine development

A core platform technology for high production of recombinant lipoproteins with built-in immuno-potentiation for novel subunit vaccine development has been established and fully protected by intellectual property. The lipid moiety of recombinant lipoproteins is identical to that of bacterial lipoproteins, which are recognized as a TLR2 agonist with effects on both innate and adaptive immunity. We have successfully demonstrated the feasibility and safety of our core platform technology in meningococcal group B subunit vaccine (MGBvac), dengue subunit vaccine and therapeutic HPV vaccine in model studies. The MGBvac has been approved by Taiwan FDA for Investigational new drug (IND). 

Viral vs non-viral vectors for gene therapy delivery

Exploring options, compare and contrast different viral and non-viral systems in the best gene therapy performance.

Exhibition Visit & Networking Lunch

Third-Generation Vaccines


Chair's Opening Remarks

Edith Jasny

Preventing infectious diseases with nucleic acid based vaccines

  • Cost effective synthesis of DNA vaccines to prevent infectious diseases
  • Using naked DNA and plasmid to induce protective immune response
  • Delivery of gene encoding vaccine antigens to stimulate infectious disease prevention
  • Vaccine design in providing rapid response time to emerging pandemics

Potential safety concerns for nucleic acid based vaccines

DNA/RNA vaccines are potential gene therapy tools which can integrate very well in plasmid and other delivery tools. However, it can also be potentially tumorigenic due to its nucleic acid nature. How do you take safety into consideration to maximise the potential of nucleic acid vaccines?

Bioinformatics in reverse vaccinology (RV)

  • Using RV in identifying prospective antigens and possible vaccine candidates
  • Case study: RV in infectious diseases R&D

Exhibition Visit & Networking Refreshments

Virus-Like Particle (VLP) Vaccines & Adjuvants


VLP as efficient vaccines: Case study on infectious diseases

  • Overview of VLP vaccines and development so far
  • Duplicating success in Hepatitis B VLP in creating new generation of effective vaccines
  • Case study: Duplicating VLP success in Zika prevention

Construction of VLP expression systems and purification methods

  • Exploring different host for VLP expression
  • Using transient expression method in rapid VLP production
  • Overview of key options for purification of VLPs expressed in different host-types

Artificial VLPs as adjuvants

  • Using biomimetic antigenic nanoparticles to elicit a positive immune response to influenza
  • Drawbacks and safety concerns

Close of Phar-East 2018

last published: 07/Dec/17 03:05